Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1139 participants.

Also called NCT01335997

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,139 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01335997
  • EudraCT 2011-001007-12
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01335997. Randomized; double masking; primary purpose treatment. Start 2011-05-01 (actual); primary completion 2012-01-01 (actual). Results posted on 2016-06-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)
Condition
Primary Hypercholesterolemia
Condition
Mixed Dyslipidemia
Intervention (Drug)
ER niacin/laropiprant (ERN/LRPT)
Intervention (Drug)
ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM)
Intervention (Drug)
Simvastatin (SIM)
Intervention (Drug)
Placebo Run-In
Intervention (Drug)
SIM-matching placebo
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01335997
Content hash
7a7d50a6ecf56ab5e2eb1ec08c6f2266f445b19c47aaed3c02cdd92ab4cb66d4